



PRESS RELEASE

Stockholm, February 6, 2006

Scanditronix-Wellhöfer and RaySearch sign development and license agreement regarding quality assurance of IMRT

RaySearch Laboratories AB (publ) and Scanditronix-Wellhöfer are entering into cooperation involving new products for quality assurance of IMRT (Intensity Modulated Radiation Therapy). The companies have signed a long-term development and license agreement that will result in four new products for quality assurance of IMRT. RaySearch is a world leader in treatment planning for IMRT and in advanced software applications for radiation therapy of cancer. Scanditronix-Wellhöfer is a world leader in advanced dosimetry and quality assurance solutions for clinical and industrial applications of radiation physics. RaySearch will receive royalties and other payments in euro for the new products, which further reduces the company's exposure to the US dollar.

“It is very pleasing that we can now initiate cooperation with the leading player on the market for dosimetry equipment,” says Johan Löf, President and CEO of RaySearch Laboratories AB. “Currently, there is a great need in the clinics for new solutions in this area, since quality assurance demands substantial personnel resources. The cooperation will permit us to create effective and highly competitive systems for automated quality assurance. Scanditronix-Wellhöfer is in the absolute forefront of detector technology and has a large installed base within a market segment to which we previously did not have access. Consequently, it is a highly suitable partner for us and the agreement means a natural and exciting expansion of RaySearch's product portfolio. The goal is to develop four entirely new products, with the first expected to be on the market within about one year.”

“When it is about the continuous improvement of cancer treatment there is no time to waste,” comments Rob Plompen, President and CEO of Scanditronix-Wellhöfer. “The advanced dosimetry solutions that both companies will jointly develop will significantly increase the dosimetric accuracy before and during IMRT patient treatment. The specific competence in dose calculation and optimization algorithms makes RaySearch the ideal partner for us in bringing this new leading-edge technology to the market. RaySearch have a proven track record in the efficient development of highly advanced radiation therapy software applications. We are therefore very pleased and confident with the signed development agreement between our companies.”

IMRT is an advanced method for radiation therapy of cancer. IMRT allows higher radiation doses to be delivered to the tumor than what is possible with a conventional treatment, and at the same time reduces the risk for side effects in surrounding healthy tissue. Since IMRT treatments are complex in nature, thorough quality assurance is required to minimize deviations between the planned radiation dose distribution and the dose that is actually delivered to the patient. In the quality assurance procedure, the treatment beams' true intensity distributions are measured against the intensity distributions calculated in the treatment planning system to determine if deviations are within the defined tolerance levels. Currently, this is a highly time- and resource-consuming task for the radiation therapy clinics.

Within the framework of the cooperation with Scanditronix-Wellhöfer, RaySearch will develop advanced software that supports and improves the efficiency of quality assurance of IMRT. Scanditronix-Wellhöfer will further develop its dosimetry platform to facilitate in a more refined manner the determination of the beam's physical properties and to achieve more rapid and accurate measurements. By combining RaySearch's dose calculation algorithms and visualization framework with Scanditronix-Wellhöfer's dosimetry competence and innovative detector technology and software, an effective and user-friendly tool is created for automated quality assurance of advanced radiation therapy.

About RaySearch

RaySearch develops and sells software for radiation therapy of cancer. The products are specially developed to optimize radiation therapy and the purpose is to adapt the radiation dose to the shape of the tumor, which allows high doses to be delivered to the tumor while minimizing the dose to surrounding healthy tissue.

RaySearch, a spin-off from Karolinska Institutet, was formed in 2000. RaySearch has sold its first product, RayOptimizer, to more than 800 hospitals around the world through a licensing agreement with Philips, enabling more than a hundred thousand patients to receive improved radiation therapy. The partnership with Philips continues and sales of the products RayBiology and RayMachine began in 2004. RaySearch signed a licensing agreement with Nucletron at the beginning of 2004. The latter agreement made RaySearch's products available to a large number of new clinics worldwide and, consequently, increased the number of potential end customers sharply. Delivery to clinics of OM-Optimizer, the first product based on the partnership with Nucletron, began in April 2005. In May 2005, RaySearch signed a Letter of Intent with Philips for development of products within adaptive radiation therapy.

RaySearch was listed on the Stockholm Stock Exchange's O-List in November 2003 and as of July 1, 2005, RaySearch is listed in the Attract40 segment. RaySearch is based in Stockholm and currently has 28 employees.

Company's website: www.raysearchlabs.com

About Scanditronix-Wellhöfer / IBA

With more than 30 years experience, Scanditronix-Wellhöfer provides sophisticated and customized high-end dosimetry and quality assurance solutions for use in hospitals and by industry partners across the world. Access to national and international research partners, as well as in-house research and design activities are the foundation of successful and reliable products for a wide range of dosimetry applications in radiotherapy and radiodiagnostics.

Company's website: www.scanditronix-wellhofer.com

Scanditronix-Wellhöfer is a fully owned daughter company of the Belgium IBA group. IBA delivers solutions of a unique precision in the fields of cancer diagnosis and therapy. The company also offers sterilization and ionization solutions to improve the hygiene and safety of everyday life. IBA is listed on the pan-European stock exchange EURONEXT, is integrated into the NextEconomy market segment and belongs to BelSmall index.

Company's website: www.iba-worldwide.com

For further information, contact:

Johan Löf

President and CEO, RaySearch Laboratories AB

+46 (0)8-545 061 30

johan.lof@raysearchlabs.com